[go: up one dir, main page]

WO2002077030A3 - Modified mhc molecules whose binding to cd8 or cd4 is inhibited and use thereof - Google Patents

Modified mhc molecules whose binding to cd8 or cd4 is inhibited and use thereof Download PDF

Info

Publication number
WO2002077030A3
WO2002077030A3 PCT/GB2002/001499 GB0201499W WO02077030A3 WO 2002077030 A3 WO2002077030 A3 WO 2002077030A3 GB 0201499 W GB0201499 W GB 0201499W WO 02077030 A3 WO02077030 A3 WO 02077030A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibited
whose binding
mhc molecules
molecules
molecules whose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2002/001499
Other languages
French (fr)
Other versions
WO2002077030A2 (en
Inventor
Bent Karsten Jakobsen
Brian John Cameron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avidex Ltd
Original Assignee
Avidex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avidex Ltd filed Critical Avidex Ltd
Priority to AU2002242882A priority Critical patent/AU2002242882A1/en
Publication of WO2002077030A2 publication Critical patent/WO2002077030A2/en
Anticipated expiration legal-status Critical
Publication of WO2002077030A3 publication Critical patent/WO2002077030A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides a method of inhibiting the activity of T cells against a cell presenting molecules of a selected Major Histocompatibility Complex (MHC) type, the method comprising causing the cell to present modified molecules of the selected MHC type whose binding to CD8 or CD4 is inhibited but which can present the same peptide or peptides as unmodified molecules of the MHC type. Such modified molecules are also provided as are nucleic acids encoding them.
PCT/GB2002/001499 2001-03-27 2002-03-27 Modified mhc molecules whose binding to cd8 or cd4 is inhibited and use thereof Ceased WO2002077030A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002242882A AU2002242882A1 (en) 2001-03-27 2002-03-27 Modified mhc molecules whose binding to cd8 or cd4 is inhibited and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0107628.0 2001-03-27
GBGB0107628.0A GB0107628D0 (en) 2001-03-27 2001-03-27 Substances

Publications (2)

Publication Number Publication Date
WO2002077030A2 WO2002077030A2 (en) 2002-10-03
WO2002077030A3 true WO2002077030A3 (en) 2003-11-27

Family

ID=9911649

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/001499 Ceased WO2002077030A2 (en) 2001-03-27 2002-03-27 Modified mhc molecules whose binding to cd8 or cd4 is inhibited and use thereof

Country Status (3)

Country Link
AU (1) AU2002242882A1 (en)
GB (1) GB0107628D0 (en)
WO (1) WO2002077030A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2398300A (en) * 2003-02-17 2004-08-18 Isis Innovation Method and compositions for boosting immune response
EP3101122B1 (en) 2009-08-24 2023-06-14 Baylor College of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
ES2748652T3 (en) 2012-02-09 2020-03-17 Baylor College Medicine Pep mixes to generate multiviral CTLs with broad specificity
AU2016324479B2 (en) 2015-09-18 2022-12-01 Baylor College Of Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
BR112022001596A2 (en) * 2019-07-29 2022-06-07 Baylor College Medicine Antigen-specific t-cell banks and methods for producing and using them therapeutically
US20220275051A1 (en) * 2019-07-30 2022-09-01 University Health Network Mhc class ii molecules and methods of use thereof
AU2021364550A1 (en) * 2020-10-20 2023-06-08 Replay Holdings, Inc. Methods and compositions for cellular therapy
JP2023041117A (en) * 2021-09-13 2023-03-24 国立研究開発法人理化学研究所 Method for analyzing sequence of side effect-related gene of drug and primer set for use therein

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021576A1 (en) * 1997-10-28 1999-05-06 Avidex Ltd. Cd8 as an inhibitor of the cellular immune system
WO2001044296A1 (en) * 1999-12-17 2001-06-21 Avidex Limited Methods of inhibiting the binding of a cd8+ t cell to a class i mhc employing a modified beta 2 microglobulin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021576A1 (en) * 1997-10-28 1999-05-06 Avidex Ltd. Cd8 as an inhibitor of the cellular immune system
WO2001044296A1 (en) * 1999-12-17 2001-06-21 Avidex Limited Methods of inhibiting the binding of a cd8+ t cell to a class i mhc employing a modified beta 2 microglobulin

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
GAO G F ET AL: "Molecular interactions of coreceptor CD8 and MHC class I: the molecular basis for functional coordination with the T-cell receptor", IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 21, no. 12, 1 December 2000 (2000-12-01), pages 630 - 636, XP004225441, ISSN: 0167-5699 *
GAO GEORGE F ET AL: "Classical and nonclassical class I major histocompatibility complex molecules exhibit subtle conformational differences that affect binding to CD8alphaalpha", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 275, no. 20, 19 May 2000 (2000-05-19), pages 15232 - 15238, XP002161627, ISSN: 0021-9258 *
KOENIG R ET AL: "MHC CLASS II INTERACTION WITH CD4 MEDIATED BY A REGION ANALOGOUS TO THE MHC CLASS I BINDING SITE FOR CD8", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 356, no. 6372, 30 April 1992 (1992-04-30), pages 796 - 798, XP001119906, ISSN: 0028-0836 *
KOENING R ET AL: "INVOLVEMENT OF BOTH MAJOR HISTOCOMPATIBILITY COMPLEX CLASS II ALPHAAND BETA CHAINS IN CD4 FUNCTION INDICATES A ROLE FOR ORDERED OLIGOMERIZATION IN T CELL ACTIVATION", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 182, 1 September 1995 (1995-09-01), pages 779 - 787, XP000647686, ISSN: 0022-1007 *
MADRENAS JOAQUIN ET AL: "The efficiency of CD4 recruitment to ligand-engaged TCR controls the agonist/partial agonist properties of peptide-MHC molecule ligands.", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 185, no. 2, 1997, pages 219 - 229, XP002233462, ISSN: 0022-1007 *
SALTER R D ET AL: "A binding site for the T-cell co-receptor CD8 on the alpha3 domain of HLA-A2", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 345, 3 May 1990 (1990-05-03), pages 41 - 46, XP002137488, ISSN: 0028-0836 *
SEWELL A K ET AL: "ANTAGONISM OF CYTOTOXIC T-LYMPHOCYTE ACTIVATION BY SOLUBLE CD8", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 5, no. 4, April 1999 (1999-04-01), pages 399 - 404, XP000996087, ISSN: 1078-8956 *
SUN J ET AL: "INTERACTION BETWEEN CD8 AND MAJOR HISTOCOMPATIBILITY COMPLEX (MCH) CLASS I MEDIATED BY MULTIPLE CONTACT SURFACES THAT INCLUDE THE ALPHA2 AND ALPHA3 DOMAINS OF MHC CLASS I", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 182, no. 5, November 1995 (1995-11-01), pages 1275 - 1280, XP009001830, ISSN: 0022-1007 *

Also Published As

Publication number Publication date
WO2002077030A2 (en) 2002-10-03
AU2002242882A1 (en) 2002-10-08
GB0107628D0 (en) 2001-05-16

Similar Documents

Publication Publication Date Title
AU2002307797A1 (en) Method of identifying peptides capable of binding to mhc molecules, peptides identified thereby and their uses
WO2003095636A3 (en) Activation induced deaminase (aid)
WO2002042424A3 (en) Seed-preferred regulatory elements and uses thereof
WO2002005146A3 (en) Method for disigning protein libraries with altered immunogenicity
WO2002074979A3 (en) Expression profiles and methods of use
AU2001296600A1 (en) Mini-dystrophin nucleic acid and peptide sequences
WO2001075087A8 (en) Subtilisin variants
GB9709728D0 (en) Single step method
WO2003006154A3 (en) Protein design automation for designing protein libraries with altered immunogenicity
WO2002061097A8 (en) Cloning vectors and vector components
AU2001242299A1 (en) Fungal transcriptional activator useful in methods for producing polypeptides
WO2003020932A1 (en) Novel secretory proteins and dna thereof
WO2002077030A3 (en) Modified mhc molecules whose binding to cd8 or cd4 is inhibited and use thereof
AU2003213580A1 (en) Subtilisin carlsberg proteins with reduced immunogenicity
IL175021A0 (en) Chromatin insulator, its preparation and use in protein expression
WO2002074807A3 (en) Chimpanzee erythropoietin (chepo) - immunoadhesins
WO2002040668A3 (en) Proteins and dna sequences underlying these proteins used for treating inflammations
SG146662A1 (en) Method
AU2003304145A1 (en) Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the genus borrelia
WO2004035799A3 (en) Viral vectors and the use of the same for gene therapy
WO2001023560A3 (en) Isolated peptides which bind to mhc class ii molecules, and uses thereof
WO1999047558A3 (en) T cell costimulatory proteins, sequences and uses thereof
GB0104163D0 (en) Security system
WO2003020887A3 (en) Gene identification
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002708521

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002708521

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP